Payment overview · 2025
General Payments
$330.22
8 reported records · 4 companies
Healthcare provider profile · identity verified
Sangeetha Kamath, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PLAINVIEW, NY · NPI 1972567899
Verified facts
What the public records show
CMS Open Payments records show Sangeetha Kamath, MD received $330.22 in general payments during 2025 across 8 reported records.
CSL Behring accounted for 41.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| CSL Behring | Unresolved — no canonical attribution shown | $135.26 | 41.0% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $124.73 | 37.8% | 1 | 2025 |
| Heron Therapeutics, Inc. | Unresolved — no canonical attribution shown | $48.80 | 14.8% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $21.43 | 6.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $330.22 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $124.73 | 1 | 2025 |
Source payment records
|
|||||
| Kcentra Normalized: kcentra |
Biological | CSL Behring | $100.80 | 3 | 2025 |
Source payment records
|
|||||
| APONVIE Normalized: aponvie |
Drug | Heron Therapeutics, Inc. | $48.80 | 2 | 2025 |
Source payment records
|
|||||
| Haegarda Normalized: haegarda |
Biological | CSL Behring | $34.46 | 1 | 2025 |
Source payment records
|
|||||
| BRIDION Normalized: bridion |
Drug | Merck Sharp & Dohme LLC | $21.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 526 | 74 |
| Amlodipine Besylate | Amlodipine Besylate | 384 | 56 |
| Levothyroxine Sodium | Levothyroxine Sodium | 374 | 51 |
| Furosemide | Furosemide | 330 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 330 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 246 | 42 |
| Losartan Potassium | Losartan Potassium | 233 | 31 |
| Donepezil Hcl | Donepezil Hcl | 173 | 28 |
| Potassium Chloride | Potassium Chloride | 166 | 24 |
| Eliquis | Apixaban | 164 | 26 |
| Omeprazole | Omeprazole | 158 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 139 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 135 | 20 |
| Lisinopril | Lisinopril | 131 | 17 |
| Gabapentin | Gabapentin | 130 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 128 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 114 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 95 | 23 |
| Mirtazapine | Mirtazapine | 94 | 16 |
| Memantine Hcl | Memantine Hcl | 86 | 14 |
| Simvastatin | Simvastatin | 84 | 12 |
| Folic Acid | Folic Acid | 81 | suppressed |
| Carvedilol | Carvedilol | 79 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 76 | 14 |
| Metformin Hcl | Metformin Hcl | 76 | suppressed |
| Famotidine | Famotidine | 72 | 15 |
| Torsemide | Torsemide | 71 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 26 |
| Prednisone | Prednisone | 61 | 15 |
| Xarelto | Rivaroxaban | 60 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 59 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 57 | suppressed |
| Myrbetriq | Mirabegron | 56 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 55 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 54 | 23 |
| Entresto | Sacubitril/Valsartan | 50 | suppressed |
| Atenolol | Atenolol | 49 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 49 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 49 | 30 |
| Amiodarone Hcl | Amiodarone Hcl | 48 | suppressed |
| Spironolactone | Spironolactone | 46 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 45 | suppressed |
| Levetiracetam | Levetiracetam | 45 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 40 | suppressed |
| Ezetimibe | Ezetimibe | 38 | suppressed |
| Gemtesa | Vibegron | 38 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 37 | suppressed |
| Azithromycin | Azithromycin | 36 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 35 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 17 |
| Latanoprost | Latanoprost | 34 | suppressed |
| Baclofen | Baclofen | 33 | suppressed |
| Methylprednisolone | Methylprednisolone | 33 | 20 |
| Metformin Hcl Er | Metformin Hcl | 32 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 32 | suppressed |
| Nystatin | Nystatin | 31 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 29 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Valsartan | Valsartan | 28 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 25 | suppressed |
| Telmisartan | Telmisartan | 25 | suppressed |
| Allopurinol | Allopurinol | 24 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 24 | 17 |
| Divalproex Sodium | Divalproex Sodium | 24 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 20 | suppressed |
| Azathioprine | Azathioprine | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Loperamide | Loperamide Hcl | 19 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Methimazole | Methimazole | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Leflunomide | Leflunomide | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Timolol Maleate | Timolol Maleate | 17 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Repaglinide | Repaglinide | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 11 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | 13 |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Alprazolam | Alprazolam | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Alogliptin | Alogliptin Benzoate | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 11 |
| Glimepiride | Glimepiride | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Dofetilide | Dofetilide | 11 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Galantamine Er | Galantamine Hbr | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Restasis Multidose | Cyclosporine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $330.22 · 8 records | CSL Behring | APONVIE, BREZTRI, BRIDION, Haegarda, Kcentra | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error